Summary
In breast cancer, the survival rate strongly depends on the number of lymph nodes involved. A drug with a specific inhibitory activity on lymph node and organ metastases would therefore be a candidate for adjuvant therapy after surgery. Prostacyclin and its stable analogues have been shown to interfere with certain steps of the metastatic cascade and to inhibit the number of lung colonies after i.v.-inoculation of various tumor cell lines. Our data reveal that cicaprost, a metabolically stable and orally active analogue of prostacyclin, has pronounced antimetastatic effects in a series of spontaneously metastasizing rodent tumors. In the SMT 2a and 13762 MTLn3 mammary carcinomas of the rat, cicaprost given daily from the day of tumor implantation strongly inhibits the number of lung metastases as well as lymph node weights without exerting an effect on the primary tumor. Even starting treatment when palpable primary tumors are present gives a pronounced antimetastatic activity. To demonstrate that cicaprost has an effect on metastases already settled in the respective organ, treatment was started after surgical removal of the primary tumor. In the SMT 2a tumor, a strong inhibition of the number of metastases was shown. Interestingly, a perioperative treatment schedule was also effective in both models used. As primary tumor growth in vivo or proliferation in vitro remained unchanged by cicaprost, its mode of action seems to be related to one or more mechanisms of the metastatic process. In tumor cell lines expressing a functional prostacyclin receptor, stimulated tumor cell migration is inhibited and changes of differentiation status are obvious. In conclusion, cicaprost strongly inhibits lymph node and organ metastases of spontaneously metastasizing rodent mammary tumors with a mode of action different from cytostatic or antihormonal drugs.
Similar content being viewed by others
References
Bonadonna G: Evolving concepts in the systemic adjuvant treatment of breast cancer. Cancer Res 52:2127–2137, 1992
McGuire WL: Breast cancer prognostic factors. JNCI 83:154–155, 1991
Goldfarb RH, Brunson KW: Overview of current understanding of tumor spread.In: Goldfarb RH (ed) Fundamental Aspects of Cancer. Kluwer, Dordrecht, 1989, pp 28–32
Schneider MR, Schirner M: Antimetastatic prostacyclin analogs. Drugs Future 18:29–48, 1993
Pollack VA: Therapy of metastasis in animal models.In: Goldfarb RH (ed) Fundamental Aspects of Cancer. Kluwer, Dordrecht, 1989, pp 192–200
Moncada S: Biological importance of prostacyclin. Br J Pharmacol 76:3–31, 1982
Skuballa W, Schillinger E, Stürzebecher CS, Vorbrüggen H: Synthesis of a new chemically and metabolically stable prostacyclin analogue. J Med Chem 29:313–315, 1986
Stürzebecher CS, Haberey M, Müller B, Schillinger E, Schröder G, Skuballa W, Stock G, Vorbrüggen H, Witt W: Pharmacological profile of a novel carbacyclin derivative with metabolic stability and oral activity in the rat. Prostaglandins 31:95–109, 1986
Thierauch K-H, Dinter H, Stock G: Prostaglandins and their receptors: I. Pharmacologic receptor description, metabolism and drug use. J Hypertension 11:1315–1318, 1993
Honn KV, Cicone B, Skoff A: Prostacyclin: a potent antimetastatic agent. Science 212:1270–1272, 1981
Honn KV, Tang DG, Chen YQ: Platelets and cancer metastasis: more than an epiphenomenon. Semin Thromb Hemost 18:392–415, 1992
Schirner M, Schneider MR: Antimetastatic potential of the stable prostacyclin analogue cicaprost.In: Rubanyi GM, Vane J (eds) Prostacyclin: New Perspectives for Basic Research and Novel Therapeutic Indications. Excerpta Medica, Amsterdam, 1992, pp 247–275
Schirner M, Schneider MR: Cicaprost inhibits metastases of animal tumors. Prostaglandins 42:451–461, 1992
Schirner M, Schneider MR: The stable prostacyclin analogue Cicaprost inhibits metastasis of tumors of R3327 MAT Lu prostate carcinoma and SMT 2A mammary carcinoma. J Cancer Res Clin Oncol 118: 497–501, 1992
Schirner M, Lichtner RB, Schneider MR: The stable prostacyclin analogue Cicaprost inhibits metastasis to lungs and lymph nodes in the 13762NF MTLn3 rat mammary carcinoma. Clin Exp Metast 12:24–30, 1994
Schirner M, Lichtner RB, Graf H, Schneider MR: Efficacy of Cicaprost on metastasis in advanced tumor disease. 3rd Int. Conference on Eicosanoids & Other Bioactive Lipids in Cancer, Inflammation & Radiation Injury. Washington DC, Oct. 13–16, 1993
Schneider MR, Tang DG, Schirner M, Honn KV: Prostacyclin and its analogues: antimetastatic effects and mechanisms of action. Cancer Met Rev 13:349–364, 1994
Thierauch K-H, Dinter H, Stock G: Prostaglandins and their receptors: II. Receptor structure and signal transduction. J Hypertension 12:1–5, 1994
Graf H: Endothelial control of cell migration and proliferation. Eur Heart J 14 (Suppl 1):183–186, 1993
Riemann D: personal communication
Lichtner RB, Julian JA, Glasser SR, Nicolson GL: Characterization of cytokeratins expressed in metastatic rat mammary adenocarcinoma cells. Cancer Res 49:104–111, 1989
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Schneider, M.R., Schirner, M., Lichtner, R.B. et al. Antimetastatic action of the prostacyclin analogue cicaprost in experimental mammary tumors. Breast Cancer Res Tr 38, 133–141 (1996). https://doi.org/10.1007/BF01803791
Issue Date:
DOI: https://doi.org/10.1007/BF01803791